OverviewSuggest Edit

Menlo Therapeutics is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause.

TypePublic
Founded2011
HQRedwood City, CA, US
Websitemenlotherapeutics.com

Latest Updates

Employees (est.) (Jan 2018)26
Revenue (Y, 2017)$2 M
Share Price (Jan 2021)$2.2(-2%)
Cybersecurity ratingBMore

Key People/Management at Menlo Therapeutics

David Domzalski

David Domzalski

President and Chief Executive Officer, Director
Matt Wiley

Matt Wiley

Chief Commercial Officer
Iain Stuart

Iain Stuart

Chief Scientific Officer
Mutya Harsch

Mutya Harsch

General Counsel, Chief Legal Officer and Secretary
Ray Steitz

Ray Steitz

Senior Vice President, Global Human Resources
Russell Elliott

Russell Elliott

Senior Vice President, Pharmaceutical Development
Show more

Menlo Therapeutics Office Locations

Menlo Therapeutics has an office in Redwood City
Redwood City, CA, US (HQ)
200 Cardinal Way
Show all (1)

Menlo Therapeutics Financials and Metrics

Menlo Therapeutics Revenue

Menlo Therapeutics's revenue was reported to be $2 m in Y, 2017
USD

Revenue (Y, 2017)

2.0m

Market capitalization (28-Jan-2021)

82.5m

Closing stock price (28-Jan-2021)

2.2
Menlo Therapeutics's current market capitalization is $82.5 m.
USDY, 2017

Revenue

2.0m
Show all financial metrics

Menlo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Menlo Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Menlo Therapeutics Online and Social Media Presence

Embed Graph

Menlo Therapeutics News and Updates

Menlo Therapeutics Announces Pricing of Offering of Common Stock

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public off…

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merge…

Menlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goals

Menlo Therapeutics Inc. shares slid 25% in premarket trade Wednesday, after the biopharmaceutical company said a mid-stage trial of a treatment for chronic pruritus, a form of skin itching, of unknown origin failed to meet its main goal. The trial involved 233 patients and sought to show a statisti…

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of…

Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology

REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for t…

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in …
Show more

Menlo Therapeutics Blogs

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI,…

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Confe…

VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and…

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a …

VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week

BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event. Panel …

VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne

BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of…
Show more

Menlo Therapeutics Frequently Asked Questions

  • When was Menlo Therapeutics founded?

    Menlo Therapeutics was founded in 2011.

  • Who are Menlo Therapeutics key executives?

    Menlo Therapeutics's key executives are David Domzalski, Matt Wiley and Iain Stuart.

  • How many employees does Menlo Therapeutics have?

    Menlo Therapeutics has 26 employees.

  • What is Menlo Therapeutics revenue?

    Latest Menlo Therapeutics annual revenue is $2 m.

  • What is Menlo Therapeutics revenue per employee?

    Latest Menlo Therapeutics revenue per employee is $76.9 k.

  • Who are Menlo Therapeutics competitors?

    Competitors of Menlo Therapeutics include TCR CURE Biopharma, BlueRock Therapeutics and Lattice Biologics.

  • Where is Menlo Therapeutics headquarters?

    Menlo Therapeutics headquarters is located at 200 Cardinal Way, Redwood City.

  • Where are Menlo Therapeutics offices?

    Menlo Therapeutics has an office in Redwood City.

  • How many offices does Menlo Therapeutics have?

    Menlo Therapeutics has 1 office.